Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
MMSI or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MMSI vs. ALGN: Which Stock Is the Better Value Option?
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.
CVS Health (CVS) to Expand Health Care Access With New Pact
by Zacks Equity Research
CVS Health's (CVS) recent collaboration establishes new Accountable Care that focuses on health equity, coordinated care and enhanced access.
QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow
by Zacks Equity Research
QIAGEN's (QGEN) latest launch is expected to aid the clinical diagnostics labs to boost their performance.
Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now
by Zacks Equity Research
Veeva Systems' (VEEV) slew of product launches raises optimism about the stock.
Abbott's (ABT) New FDA Approval to Improve Patient Outcome
by Zacks Equity Research
Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device.
Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe
by Zacks Equity Research
Walgreens Boots (WBA) continues to progress in transforming the pharmacy business and the method of delivering healthcare through physical stores and digital channels.
Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials
by Zacks Equity Research
Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.
Charles River (CRL) to Develop RNA-based Therapy With New Pact
by Zacks Equity Research
Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.
ShockWave Medical (SWAV) Posts Solid Preliminary Q4 Revenues
by Zacks Equity Research
ShockWave Medical's (SWAV) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its U.S. Coronary business.
Cardiovascular Systems (CSII) Global Sales Up, Margin Woe Stays
by Zacks Equity Research
Cardiovascular Systems (CSII) international revenues are showing strong growth in each of the key markets, including Japan, Europe, Asia Pacific and Canada.
Here's Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome
by Zacks Equity Research
Shockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool.
Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe
by Zacks Equity Research
Edwards Lifesciences (EW) continues to witness strong momentum of the RESILIA portfolio globally.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about the strong performance of Neogen's (NEOG) Animal Safety and Food Safety segments.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI), owing to its strong product portfolio.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) strong product line.
IDEXX (IDXX) Aided by Global Growth, Solid Instrument Placement
by Zacks Equity Research
IDEXX's (IDXX) rapid assay revenue growth is supported by solid volume gains in the United States and benefits from net price increases.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
BD's (BDX) New Robotic Track System to Boost Lab Workflow
by Zacks Equity Research
BD's (BDX) new robotic track system for the BD Kiestra microbiology laboratory solution is expected to streamline lab workflows.
DENTSPLY SIRONA's (XRAY) Preliminary FY22 Sales Meet Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.
Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology
by Zacks Equity Research
Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.
Here's Why Investors Should Retain Globus Medical (GMED) Stock
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) robust performance across several international markets.
Charles River (CRL) to Advance DNA Programs With New Launch
by Zacks Equity Research
Charles River's (CRL) launch of the eXpDNA plasmid manufacturing platform is intended to support vaccine and advanced therapy clients through clinical trials and beyond.